Praecis Plenaxis Resubmission Narrows Indication; User Fee Goal In August
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Praecis’ resubmitted NDA for its prostate cancer therapy Plenaxis has a late-August user fee goal date.